#Single Nucleotide Polymorphism (SNP) Genotyping Market Scope

[soumyafwr]

Single Nucleotide Polymorphism (SNP) Genotyping Market Size, Analysis and Forecast 2031

[marketreportoutlook]

Single Nucleotide Polymorphism Genotyping Market Size, Share, Growth Opportunity and Trends by Growing CAGR till 2026

The global Single Nucleotide Polymorphism Genotyping Market research report 2021 available on DecisionDatabases covers top company players in various countries along with analyzing the market trends and growth rate. Segment analysis by types and application helps in bifurcating the Single Nucleotide Polymorphism Genotyping Market and understand each product type. This report provides information on various market factors such as market size, share, manufacturer's data, growth, and forecast till 2026

The key market players for the global Single Nucleotide Polymorphism Genotyping market are listed below:

Illumina

Luminex Corporation

Agilent Technologies

Affymetrix

Qiagen

Applied Biosystems

Bio-rad

Roche

Beckman Coulter

Enzo Life Sciences

Douglas Scientific

HuaGene Biotech

Sequenom

Benegene

BGI

GenScript

Ocimum Biosolutions

Generay Biotech

Beijing Sunbiotech

Others

Click here to get a FREE Sample Copy of the Single Nucleotide Polymorphism Genotyping Market Research Report @ https://www.decisiondatabases.com/contact/download-sample-26639

The Global Single Nucleotide Polymorphism (SNP) Genotyping Market Report is equipped with market data from 2016 to 2026. The report gives a market overview covering key drivers and risk factors. The report is bifurcated by top global manufactures mentioning sales, revenue, and prices as applicable. It also evaluates the competitive scenario of the leading players. The report expands to cover regional market data along with type and application. The report forecasts sales and revenue from 2021 to 2026. The detailed sales channel is also covered in the study.

COVID-19 Impact Analysis on Single Nucleotide Polymorphism Genotyping Market

The global pandemic COVID-19 has affected the Single Nucleotide Polymorphism (SNP) Genotyping market directly or indirectly. This study covers a separate section giving an explicitly clear understanding of the aftereffects of this pandemic. The detailed study highlights the probable outcomes of this global crisis on the Single Nucleotide Polymorphism (SNP) Genotyping industry. The impact study on production, supply-demand, and sales provides a holistic approach to the future.

Do You Have Any Query Or Report Customization? Ask Our Market Expert @ https://www.decisiondatabases.com/contact/ask-questions-26639

Why Purchase this Report?

A robust research methodology has been followed to collect data for the report. Data, thus collected passes through multiple quality checks to ensure the best quality is served.

The report gives a holistic view of the competitive scenario of the Single Nucleotide Polymorphism (SNP) Genotyping market

The latest product launches along with technological changes and development are covered in the report.

The data analysis in the report helps in understanding the anticipated Single Nucleotide Polymorphism (SNP) Genotyping market dynamics from 2021 to 2026.

DecisionDatabases has a vast repository of data, therefore, we can accommodate customized requirements also.

The graphs, tables and pie charts, and info-graphics covered in the report will help in a better understanding of the report.

The market drivers, restraints, upcoming opportunities, and anticipated restraints cited in the report will assist in making an informed decision.

To better understand the market scenario, the Single Nucleotide Polymorphism (SNP) Genotyping market is segmented as below:

By Types:

Transversion

Transition

By Applications:

Diagnostics

Animal

Plant

Research

Others

By Regions:

North America (U.S., Canada, Mexico)

Europe (U.K., France, Germany, Spain, Italy, Central & Eastern Europe, CIS)

Asia Pacific (China, Japan, South Korea, ASEAN, India, Rest of Asia Pacific)

Latin America (Brazil, Rest of L.A.)

The Middle East and Africa (Turkey, GCC, Rest of Middle East)

The content of the study subjects includes a total of 14 chapters:

Chapter 1: To describe Single Nucleotide Polymorphism (SNP) Genotyping product scope, market overview, market opportunities, market driving force, and market risks. Chapter 2: To profile the top manufacturers of Single Nucleotide Polymorphism (SNP) Genotyping, with price, sales, revenue, and global market share of Single Nucleotide Polymorphism (SNP) Genotyping in 2018 and 2019. Chapter 3: The Single Nucleotide Polymorphism (SNP) Genotyping competitive situation, sales, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast. Chapter 4: The Single Nucleotide Polymorphism (SNP) Genotyping breakdown data are shown at the regional level, to show the sales, revenue, and growth by region, from 2015 to 2020. Chapter 5 and 6: To segment the sales by type and application, with sales market share and growth rate by type, application, from 2015 to 2020. Chapter 7, 8, 9, 10 & 11: To break the sales data at the country level, with sales, revenue, and market share for key countries in the world, from 2016 to 2021 and Single Nucleotide Polymorphism (SNP) Genotyping market forecast, by regions, type, and application, with sales and revenue, from 2021 to 2026. Chapter 12, 13 & 14: To describe Single Nucleotide Polymorphism (SNP) Genotyping sales channel, distributors, customers, research findings and conclusion, appendix, and data source.

Directly Purchase the Complete Global Single Nucleotide Polymorphism Genotyping Market Research Report @ https://www.decisiondatabases.com/contact/buy-now-26639

About Us:

DecisionDatabases.com is a global business research report provider, enriching decision-makers, and strategists with qualitative statistics. DecisionDatabases.com is proficient in providing syndicated research reports, customized research reports, company profiles, and industry databases across multiple domains. Our expert research analysts have been trained to map client’s research requirements to the correct research resource leading to a distinctive edge over its competitors. We provide intellectual, precise, and meaningful data at a lightning speed.

For more details: DecisionDatabases.com E-Mail: sales@decisiondatabases.com Phone: +91 90 28 057900 Web: https://www.decisiondatabases.com/

[the-madhuri]

Global Biochip Scanner Market-Industry Analysis and Forecast (2019-2027) – By Type, End User, and Region.

Global biochip scanner market size was US$ XX Bn in 2019 and is expected to reach US$ XX Bn by 2027, at a CAGR of ~18% during the forecast period.

Global Biochip Scanner Market

The report study has analyzed the revenue impact of COVID -19 pandemic on the sales revenue of market leaders, market followers, and market disrupters in the report, and the same is reflected in our analysis.

Market Definition

Biochips are miniature version of the laboratories and are the most significant part of molecular biology. Biochips are generally used to perform thousands or hundreds of biochemical reactions at the same time. A biochip scanner is a device that is used to discover and obtain fluorescence signal data from biochips or biological microchips and these devices consist of a laser to emit a laser beam and scan the particular rows of the biochips.

Market Dynamics

A biochip scanner market has witnessed an ample growth from the past few years. The growth of the biochip scanner market is primarily driven by its growing significance in various biomedical applications. An increasing requirement to reduce turnaround time, rising demand of biochip scanners for researches and diagnostics activities to perform clinical tests, growing technological advancements and rising applications of biochips, ongoing research and development activities in large-scale genomic and proteomic field and advances in nanotechnology are expected to improve growth of the market during the forecast period.

However, high cost of biochip scanners, risks of hazardous problems of individual privacy and high complexity of biological systems are major restraining factors that could hamper the growth of the market.

Global Biochip Scanner Market: Segmentation Analysis

By type, the DNA chip segment dominated the market in 2019 and is projected to witness fast growth at a CAGR of XX% during the forecast period. Increasing investments in research activities and rising demand for next-generation and advanced genetic disorder diagnosis and detection tools are attributed to the growth of the market. A rising adoption of DNA chips in applications such as gene expression profiling, to identify novel drugs, to discover the dissimilarities in gene expression levels in cells and to detect the mutations in specific genes is expected to improve growth of the market during the forecast period.

Global Biochip Scanner Market: Regional Analysis

Region-wise, North America held the largest market share in 2019 and is expected to maintain its dominance at a CAGR of XX% during the forecast period. The US and Canada are the major key contributors behind the growth of the market. The growth is attributed to the growing technological advancements in the biomedical field across the region.

Growing adoption of biochip scanners in research laboratories and increasing use of biochip scanning technology in drug development, clinical research, toxicology studies, diagnostics and in various clinical trials is driving the growth of the market in the NA region.

The objective of the report is to present a comprehensive analysis of the Global Biochip Scanner Market including all the stakeholders of the industry. The past and current status of the industry with forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers all the aspects of the industry with a dedicated study of key players that includes market leaders, followers, and new entrants. PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors of the market have been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give a clear futuristic view of the industry to the decision-makers. The report also helps in understanding Global Biochip Scanner Market dynamics, structure by analyzing the market segments and projects the Global Biochip Scanner Market. Clear representation of competitive analysis of key players by Application, price, financial position, Product portfolio, growth strategies, and regional presence in the Global Biochip Scanner Market make the report investor’s guide.

For more information visit the link given belowhttps://www.maximizemarketresearch.com/market-report/global-biochip-scanner-market/70484/

The Scope of Global Biochip Scanner Market

Global Biochip Scanner Market, By Type

• DNA Chips • Lab-On-A-Chip • Protein Chips • Cancer Diagnosis and Treatment • Gene Expression • Single Nucleotide Polymorphism (SNP) Genotyping • Genomics • Drug Discovery • Others (Agricultural Biotechnology, Proteomics, Expression Profiling, High Throughput Screening) Global Biochip Scanner Market, By End User

• Biotechnology & Pharmaceutical Companies • Hospitals & Diagnostics Centers • Academic & Research Institutes Global Biochip Scanner Market, By Region

• North America  US  Canada • Europe  UK  France  Germany  Italy  Spain  Norway  Russia • Asia Pacific  China  India  Japan  South Korea  Australia  Malaysia  Indonesia • South America  Brazil  Mexico  Argentina • Middle East and Africa Global Biochip Scanner Market, Key Players

• Agilent Technologies, Inc • Bio-Rad Laboratories, Inc • Cepheid Inc • Fluidigm Corporation • GE Healthcare • Hoffman-La-Roche Ltd • Illumina, Inc • Ocimum Biosolutions Ltd • PerkinElmer, Inc • Takara Bio Inc • Thermo Fisher Scientific Inc • Merck Millipore • Sigma-Aldrich Corporation • Abbott Laboratories • XX • XX

This report is submitted by Maximize market Research Company

Customization of the report:

Maximize Market Research provides free personalized of reports as per your demand. This report can be personalized to meet your requirements. Get in touch with us and our sales team will guarantee provide you to get a report that suits your necessities.

About Maximize Market Research:

Maximize Market Research provides B2B and B2C research on 20,000 high growth emerging opportunities & technologies as well as threats to the companies across the Healthcare, Pharmaceuticals, Electronics & Communications, Internet of Things, Food and Beverages, Aerospace and Defense and other manufacturing sectors.

Contact info:

Name: Lumawant Godage

Organization Address: MAXIMIZE MARKET RESEARCH PVT. LTD.

Email: sales@maximizemarketresearch.com

Address: Omkar Heights, Sinhagad Road, Manik Baug, Vadgaon Bk,Pune, Maharashtra 411051, India.

Contact: +919607195908

[perfectdonutobservation]

Global biochip scanner market

Global biochip scanner market size was US$ XX Bn in 2019 and is expected to reach US$ XX Bn by 2027, at a CAGR of ~18% during the forecast period.

Global Biochip Scanner Market

The report study has analyzed the revenue impact of COVID -19 pandemic on the sales revenue of market leaders, market followers, and market disrupters in the report, and the same is reflected in our analysis.

Market Definition

Biochips are miniature version of the laboratories and are the most significant part of molecular biology. Biochips are generally used to perform thousands or hundreds of biochemical reactions at the same time. A biochip scanner is a device that is used to discover and obtain fluorescence signal data from biochips or biological microchips and these devices consist of a laser to emit a laser beam and scan the particular rows of the biochips.

Market Dynamics

A biochip scanner market has witnessed an ample growth from the past few years. The growth of the biochip scanner market is primarily driven by its growing significance in various biomedical applications. An increasing requirement to reduce turnaround time, rising demand of biochip scanners for researches and diagnostics activities to perform clinical tests, growing technological advancements and rising applications of biochips, ongoing research and development activities in large-scale genomic and proteomic field and advances in nanotechnology are expected to improve growth of the market during the forecast period.

However, high cost of biochip scanners, risks of hazardous problems of individual privacy and high complexity of biological systems are major restraining factors that could hamper the growth of the market.

Global Biochip Scanner Market: Segmentation Analysis

By type, the DNA chip segment dominated the market in 2019 and is projected to witness fast growth at a CAGR of XX% during the forecast period. Increasing investments in research activities and rising demand for next-generation and advanced genetic disorder diagnosis and detection tools are attributed to the growth of the market. A rising adoption of DNA chips in applications such as gene expression profiling, to identify novel drugs, to discover the dissimilarities in gene expression levels in cells and to detect the mutations in specific genes is expected to improve growth of the market during the forecast period.

Global Biochip Scanner Market: Regional Analysis

Region-wise, North America held the largest market share in 2019 and is expected to maintain its dominance at a CAGR of XX% during the forecast period. The US and Canada are the major key contributors behind the growth of the market. The growth is attributed to the growing technological advancements in the biomedical field across the region.

Growing adoption of biochip scanners in research laboratories and increasing use of biochip scanning technology in drug development, clinical research, toxicology studies, diagnostics and in various clinical trials is driving the growth of the market in the NA region.

The objective of the report is to present a comprehensive analysis of the Global Biochip Scanner Market including all the stakeholders of the industry. The past and current status of the industry with forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers all the aspects of the industry with a dedicated study of key players that includes market leaders, followers, and new entrants. PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors of the market have been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give a clear futuristic view of the industry to the decision-makers. The report also helps in understanding Global Biochip Scanner Market dynamics, structure by analyzing the market segments and projects the Global Biochip Scanner Market. Clear representation of competitive analysis of key players by Application, price, financial position, Product portfolio, growth strategies, and regional presence in the Global Biochip Scanner Market make the report investor’s guide. The Scope of Global Biochip Scanner Market

Global Biochip Scanner Market, By Type

• DNA Chips • Lab-On-A-Chip • Protein Chips • Cancer Diagnosis and Treatment • Gene Expression • Single Nucleotide Polymorphism (SNP) Genotyping • Genomics • Drug Discovery • Others (Agricultural Biotechnology, Proteomics, Expression Profiling, High Throughput Screening) Global Biochip Scanner Market, By End User

• Biotechnology & Pharmaceutical Companies • Hospitals & Diagnostics Centers • Academic & Research Institutes Global Biochip Scanner Market, By Region

• North America  US  Canada • Europe  UK  France  Germany  Italy  Spain  Norway  Russia • Asia Pacific  China  India  Japan  South Korea  Australia  Malaysia  Indonesia • South America  Brazil  Mexico  Argentina • Middle East and Africa Global Biochip Scanner Market, Key Players

• Agilent Technologies, Inc • Bio-Rad Laboratories, Inc • Cepheid Inc • Fluidigm Corporation • GE Healthcare • Hoffman-La-Roche Ltd • Illumina, Inc • Ocimum Biosolutions Ltd • PerkinElmer, Inc • Takara Bio Inc • Thermo Fisher Scientific Inc • Merck Millipore • Sigma-Aldrich Corporation • Abbott Laboratories • XX • XX For More Information Visit @: https://www.maximizemarketresearch.com/

This Report Is Submitted By :Maximize Market Research Company Customization of the report: Maximize Market Research provides free personalized of reports as per your demand. This report can be personalized to meet your requirements. Get in touch with us and our sales team will guarantee provide you to get a report that suits your necessities.

About Maximize Market Research: Maximize Market Research provides B2B and B2C research on 20,000 high growth emerging opportunities & technologies as well as threats to the companies across the Healthcare, Pharmaceuticals, Electronics & Communications, Internet of Things, Food and Beverages, Aerospace and Defense and other manufacturing sectors. Contact info: Name: LumawantGodage Organization Address: MAXIMIZE MARKET RESEARCH PVT. LTD. Email: sales@maximizemarketresearch.com Address:Pune, Maharashtra 411051, India. Contact: +919607195908

[healthcarepharma-blog]

Global Single Nucleotide Polymorphism (SNP) Genotyping Market- Positive Long-Term Growth Outlook 2017-2022

Geographically, this report is segmented into several key Regions, with production, consumption, revenue (million USD), market share and growth rate of Single Nucleotide Polymorphism (SNP) Genotyping in these regions, from 2012 to 2022 (forecast), covering North America Europe China Japan Southeast Asia India

 Get Exclusive sample copy @ https://www.researchtrades.com/request-sample/1228806

 Global Single Nucleotide Polymorphism (SNP) Genotyping market competition by top manufacturers, with production, price, revenue (value) and market share for each manufacturer; the top players including Illumina Affymetrix BGI Beijing Sunbiotech

On the basis of product, this report displays the production, revenue, price, market share and growth rate of each type, primarily split into Type I Type II

On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, consumption (sales), market share and growth rate of Single Nucleotide Polymorphism (SNP) Genotyping for each application, including Diagnostics Animal Plant Research Others

Buy a single user copy of this Report For the price of USD 2900 @ https://www.researchtrades.com/checkout/1228806

 Table of Contents 1 Single Nucleotide Polymorphism (SNP) Genotyping Market Overview 1.1 Product Overview and Scope of Single Nucleotide Polymorphism (SNP) Genotyping 1.2 Single Nucleotide Polymorphism (SNP) Genotyping Segment by Type (Product Category) 1.3 Global Single Nucleotide Polymorphism (SNP) Genotyping Segment by Application

2 Global Single Nucleotide Polymorphism (SNP) Genotyping Market Competition by Manufacturers 2.1 Global Single Nucleotide Polymorphism (SNP) Genotyping Capacity, Production and Share by Manufacturers (2012-2017) 2.2 Global Single Nucleotide Polymorphism (SNP) Genotyping Revenue and Share by Manufacturers (2012-2017) 2.3 Global Single Nucleotide Polymorphism (SNP) Genotyping Average Price by Manufacturers (2012-2017) 3 Global Single Nucleotide Polymorphism (SNP) Genotyping Capacity, Production, Revenue (Value) by Region (2012-2017) 3.1 Global Single Nucleotide Polymorphism (SNP) Genotyping Capacity and Market Share by Region (2012-2017) 3.2 Global Single Nucleotide Polymorphism (SNP) Genotyping Production and Market Share by Region (2012-2017) 3.3 Global Single Nucleotide Polymorphism (SNP) Genotyping Revenue (Value) and Market Share by Region (2012-2017)

….

Browse This Report @ https://www.researchtrades.com/report/global-single-nucleotide-polymorphism-snp-genotyping-market-research-report-2017/1228806

 Who we are

Research Trades has team of experts who works on providing exhaustive analysis pertaining to market research on a global basis. This comprehensive analysis is obtained by a thorough research and study of the ongoing trends and provides predictive data regarding the future estimations, which can be utilized by various organizations for growth purposes.

 Reach at us:

Email: sales@researchtrades.com

Call us: +1 6269994607 (USA), +91 7507349866 (IND)

Web: http://www.researchtrades.com

Skype ID: researchtradescon.

[nancygduarteus]

Can Your DNA Tell You the Healthiest Way to Live Your Life?

A double helix begins to swirl on my screen after I upload the raw data from my 23andMe genetic test to a site called DNA Lifestyle Coach. An ethnically ambiguous illustrated girl greets me, gleefully eating a bowl of vegetables while holding her cell phone. Against a salmon-colored backdrop are the words: “MY DIET COACH,” offering a health plan “tailored” to my genetics.

Here is what the DNA Lifestyle Coach, run by a company called Titanovo, promises: For between $215 and $320, it will send you a saliva kit and analyze your genes to determine how you should best live your life for optimal mental and physical health, as well as optimal dental and skin care. For another $150 it will measure the length of your telomeres (the protective caps on the ends of our chromosomes, which typically shrink as we get older and are being studied to understand aging), to help you assess your longevity. You can also bypass Titanovo’s DNA test and instead merge data you’ve already received from 23andMe (as I did) or another testing company.

DNA Lifestyle Coach is one in a batch of companies that has emerged in recent years, promising to pare down confusing personal DNA data reports, using science, leaving you instead with a simple set of bullet points for how to live healthier, happier, stronger, smarter, longer.

There’s DNAFit. And Kinetic Diagnostics. And even a “genetic superhero test” by Orig3n, which makes DNA-based predictions about your strength, intelligence, and speed. Most of these are aimed at boosting athletic and physical performance and preventing sports-related injuries. But DNA Lifestyle Coach ventures into cosmetic and stress-reduction advice, seeking to answer questions like: What can our genes tell us about how we can sleep better? What secrets does my DNA hold about preventing aging?

As I begin to read my report, DNA Lifestyle Coach informs me: “Your genetics infer that you will struggle to lose weight more than most, so your caloric cut should be strict.” When dieting, it says, I should aim to take in 600 fewer calories a day.

At first glance, this information does not feel more enlightening than any other diet or fitness plan I have ever tried in my life. Plug my weight, height, BMI numbers and heart rate averages into apps like MyFitnessPal or Fitbit and each one will spit out similar estimates. Tell me something I don’t know. Then, it does.

According to my genes, it says up to three cups of coffee per day could be beneficial, but does not give any details as to those benefits. And the psychological effects of caffeine are supposedly less pronounced for me, which means I’m able to sleep after a couple hours even when having coffee at night. It also predicts that I sober up after alcohol quicker than most. Great! More coffee? Less intoxication? All from my genes?

It gets better. Apparently, I have awesome endurance. Like marathon runner-level endurance (if I wanted to be a professional athlete). And my DNA Lifestyle Coach says I push myself in exercise and competition. That is because I don’t have any risk for “over-anxiety,” or other “negative emotions.” I don’t think my husband would agree. But whatever. I am starting to like my genes even more.

Feeling emboldened, I sign up for the company’s telomere test, which requires sending more of my spit away in the mail. It will take several weeks to get the results back, but I have a feeling the test is going to tell me I have robust telomeres too, and that I am going to live a long, long time. It is all beginning to feel a lot like that time I had my palms read on a street corner in the French Quarter in New Orleans.

But those feel-good endorphins that come along with being told you’re superior can fade fast, and one need only dig down into the data to figure out that such an inflated sense of personal biology may not be much more than an illusion.

“You have to know, this is like the stuff you see on TV after midnight,” Stuart K. Kim tells me after I share my DNA Lifestyle Coach site password and complete health profile results with him. He’s a professor emeritus in the developmental biology and genetics program at Stanford University. “Weight loss kind of stuff, anti-aging kind of stuff. It’s pretty far out there.”

I stay on the phone with Kim as he and I click on the little information bubbles in my report next to suggestions for carbs, fats, fiber, water intake, vitamins, gluten, and lactose. In each category, the report highlights my genes and SNPs in those gene sequences (single-nucleotide polymorphisms, pronounced “snips,” which are alternative spellings of genes that come down to a one letter difference. That one letter may lead to the gene functioning differently). With each SNP comes a link to an abstract for a published academic paper (most behind a paywall) explaining how it might be associated with health.

Kim goes a step further for me. Using his own academic accounts, he kindly pulls up and reviews the studies. He gives the company credit for posting the links to the papers in the first place—allowing customers to check out some of the conclusions if they choose. “It is buyer beware. You can’t just take everything at face value.”

Problem is, as Kim begins to interpret the papers on my DNA Lifestyle Coach report in connection to my own SNPs, he can’t even make sense of it all. Kim has served as an editor of PLOS Genetics, as well as on the National Science Advisory Council. He even developed his own DNA interpretation site for a Stanford class he taught on genetics, which students (or the public) can use for free.

On the DNA Lifestyle Coach site, my SNPs + the studies = conclusions like: Your eating behavior is 50 percent likely to be hedonic (the kind of eating for pleasure that leads to obesity and is similar to addiction). Then it goes on to recommend the LEARN Diet for my genotype. Yet there is no clear answer on how exactly the company came to that assessment.

At one point, I hear Kim say in frustration, “Maybe they are just assuming nobody is going to actually look at what they are saying? You almost have to be a detective to sit down and figure this stuff out.”

* * *

“We try to be open and honest about where the science is,” says Corey McCarren, the chief operating officer for Titanovo. The company launched after a successful Kickstarter campaign last year. McCarren’s specialty is marketing, not genetics, but he notes that his founding partner and CEO, Oleksandr Savsunenko, has a Ph.D. in macromolecular chemistry from France’s Toulouse University, and created the company’s telomere length testing kit.

“The science is now in a place where there are very strong correlations” between particular gene variations and health outcomes, McCarren says. Big data—the analysis of large amounts of data to identify patterns and make predictions—is now being used in a multitude of industries, as McCarren points out. The company believes that big data can also be successfully “applied to genetics, using probabilistic approaches.”

Studies referenced on DNA Lifestyle Coach have been published in academic journals. But some research is better proven than others, he says, and the company tries to give weight to the stronger studies. The journals vary in distinction, the studies vary in size and scope, and some experiments have been replicated, while others–like this one on how cloudy apple juice may be healthier for some genotypes—have not.

The DNA Lifestyle Coach algorithm ranks studies, giving more weight to those that are more prominent or corroborated. As research results are updated, retracted, or reaffirmed, the algorithm will also revise and update the customer’s report. The company plans to release its mental wellness, dental, and skincare tests in a few months (so far you can just get results for diet fitness and telomeres).

In the future, it plans to incorporate personal data on every individual’s daily health behavior, if users opt in to answer questions about themselves, “much like Facebook and Google are taking all the big data from what people are doing online and making assumptions about people,” McCarren says. “That’s what we want to do. We want to discover those important correlations that will lead to people able to live their best lives.”

“We don’t show all the studies” that are referenced and averaged, Savsunenko explains, when I ask about the methodology. “The number of exact studies that we used and combined in order to generate the result — it is our proprietary thing. Although in reality most of the recommendations are based on the quite simple genetic and mathematical approaches.”

Fair enough. But the equations behind the inferences still feel a bit like voodoo.

Take my alcohol results: I will sober up quickly, and “alcohol consumption will likely lead to hangovers.” This is followed by 10 of my SNPs and links to six scholarly articles covering how genes are related to everything from drinking behavior and intensity, urges to drink, and alcoholism risk.

But DNA Lifestyle Coach fails to mention anything about the ALDH2 gene variant, which I already know I have, thanks to 23andMe. It causes a reaction known as “Asian flush.” My body lacks the enzyme that normally breaks down acetaldehyde, a toxic substance in alcohol.  It builds up to abnormal levels even after half a glass of wine, causing the blood vessels in my face begin to expand. My skin turns the color of my merlot. My heart races. Within 15 minutes, my face and chest look hot to the touch, as if I accidentally fell asleep on the beach. People with this gene variant also have an increased risk for esophageal cancer.

Kim, who also experiences the same genetic pinkish glow when he drinks alcohol, was surprised my DNA Lifestyle Coach omitted it entirely.

When I ask Savsunenko about it, he replies that most people who have this gene already know they have it. “We are trying to get into smaller details of things. But, yeah, you are right—we should include it maybe.”

No matter what you include or omit, or how you add up and average it, genomic data interpretation is an ethically thorny and legally risky business. I wanted to know, not only if these algorithmic conclusions are safe, but if they are legal.

* * *

In the most romantic of gestures, my husband bought me a 23andMe saliva kit for my birthday in 2015. That was two years after 23andMe received an FDA warning to stop interpreting specific health data from its genetic tests.

Using a medical device like a DNA kit and relying on companies’, rather than doctors’, interpretations of our unsupervised genetic information from those kits, the FDA said, might lead a patient to undergo unnecessary surgeries to prevent cancer, increase or decrease doses or stop a doctor’s prescriptions and therapy altogether.

By the time I received my 23andMe results, the company had switched to focusing more on ancestry (it told me I am 50 percent East Asian and 50 percent European—no shocker), other traits like eye color (I’m likely to have dark-colored eyes—also duh), whether I can detect taste bitter or sweet tastes (it told me I like both), or if I’m more likely to sneeze in the sun (apparently I am). My report was mildly entertaining for a few hours, but it revealed no real life-altering information. I didn’t open it again until last month, when I dumped its contents into DNA Lifestyle Coach.

By then, the FDA had softened its stance on 23andMe’s tests and granted the company approval to tell its customers whether they have an increased risk for 10 specific conditions. These include Parkinson’s, late onset Alzheimer’s, Celiac disease, and a handful of other disorders that can affect movement, blood clotting, digestion or other health issues. My updated 23andMe report offered the reassuring words “variant not detected” alongside each of the conditions.

But in the years since the legal drama first began to unfold with 23andMe, other sites were ramping up, carefully tiptoeing around the kind of rules that could get them a cease and desist letter from the FDA.

DNA Lifestyle Coach has avoided this controversy, for now, by steering clear of medical discussions, McCarren tells me. When a genetic test company tells a customer: “You have nine times more likelihood of developing heart disease—take two aspirin a day,” he believes that is when the legal terrain gets murky. DNA Lifestyle Coach “is not a product to help you manage disease,” he says. “This is a product to help you make better lifestyle decisions.”

It’s not so different from seeking advice from a personal trainer at your gym, or a diet and fitness book on Amazon, McCarren says. Maybe you will see health improvements, maybe not, but you won’t get a medical diagnosis and you won’t risk doing any real harm. The difference, he adds, is “that there is strong enough evidence there to give people useful advice, which is better than just throwing a dart at a (diet) board and saying, ‘I’ll go with this one.’”

Most of these companies rely on similar data sets and “package it in different ways to try to make it understandable,” Barry Starr, another geneticist from Stanford University, tells me. “I was trying to think of a result that would make me change my lifestyle—I couldn’t think of one.”

There is just still so much geneticists still do not know, Starr says. Just because 23andMe cleared me of variants for 10 conditions does not at all mean I won’t still develop any one of them. One gene sequence is most likely part of an orchestra of a dozen or even a hundred others (many not yet identified)—all interacting to create a particular result. We also have gene sequences that protect us—which can counteract the “bad” SNP affects.

Your environment, the way you were reared and raised, and every choice you’ve made about your life until now may have had an impact on whether some of your genes are turned on, or “expressed” (as studied in the growing field of epigenetics). And Starr tells me that different DNA sequencing companies test different genes, which could lead to contradictory predictive health outlooks.

*  *  *

In the wake of the FDA’s 23andMe ban, Kim’s students became enamored by the debate over how much you have a right to know about your own genes. Some argued “I have a right to know. It’s my DNA. I’m allowed to use my brain to look at my own DNA,” Kim tells me. But others asserted that, “interpretation can go awry. Someone could make a stupid decision and hurt themselves.”

DNA Lifestyle Coach piques my interest enough to seek out more data. For just $5, I also sign up for Promethease, a genomic information clearinghouse. Again, I plug in my 23andMe raw results.

Promethease avoids the FDA regulations imposed upon 23andMe because it does not offer the spit kit. Promethease takes the raw results from 23andMe or Ancestry.com and runs it all against published academic genetic studies in SNPedia (created by the founders of Promethease), which is like a Wikipedia for genomic data, giving you a far more sweeping view of your DNA than either 23andMe or DNA Lifestyle Coach.

When I download my Promethease file, compiled on the screen before me into a mind-numbing document of multi-colored pie graphs, are 20,269 of my SNPs, looking for associations with everything from enhanced hippocampal volume, to better performing muscles, to worse hang overs, lack of empathy, longevity and gout. They are divided by colors: red for “bad” impact, green for “good,” and grey for “not set,” or not enough information to know.

In filtering first for only the “bad” as any morbidly curious person would (is there a SNP for that?) it seems my DNA is beset by perilous risks: melanoma, ovarian cancer, depression, obesity, schizophrenia, coronary artery disease, breast cancer, lung cancer, colorectal cancer, and of course Alzheimer’s and Parkinson’s. Depending on how you look at my Promethease report, I’m also at risk for age-related macular degeneration, or I’m not. I’m at risk for developing Crohn’s Disease, or wait, maybe not. Different SNPs contradict each other.

Should I run this by a doctor? I wonder. Or a genetic counselor? What does one do with such a vomit pile of personal data?

It is this very conundrum that could give a company like DNA Lifestyle Coach—as its algorithms get more sophisticated—an upper hand with the public in the future. “We are focused on actionable results, McCarren says. “We assume our customers are not interested in just the genetic reports…we are not trying to overload you with the information.”

* * *

With my own DNA bible now at my fingertips, I still do not feel any more informed about my own health future than I did before. Despite DNA Lifestyle Coach’s fortune cookie-like predictions, I still embrace our inability to foretell most outcomes. My father has diabetes. My grandfather had heart disease. My grandmother had breast cancer. I always knew I could end up with each of these conditions, or I could dodge them altogether.

As dazzling as it is to see our DNA sequenced for so little cost, it is premature for us to map out life plans exclusively based on our genes. Of course, with science progressing so rapidly, that could change in years to come. My telomere test results, which took about two months to come back, indicate that I just might just live long enough to witness that future.

Longer telomeres have been associated with more resilient cellular health. My telomeres are longer than 59 percent of women of my age, according to the test results, which puts me in the “Very Good Zone.” It did not offer me any suggestions to improve my telomere length, although studies have found that meditation and reduced stress could have an impact. Instead, it gave me a calculation of my biological age (35), which is three years younger than my actual age. At the end of the results page, it also offered this caveat: “Keep in mind the full dynamics of telomere length have yet to be discovered.”

from Health News And Updates https://www.theatlantic.com/health/archive/2017/06/can-your-dna-tell-you-the-healthiest-way-to-live-your-life/531885/?utm_source=feed

[ionecoffman]

Can Your DNA Tell You the Healthiest Way to Live Your Life?

A double helix begins to swirl on my screen after I upload the raw data from my 23andMe genetic test to a site called DNA Lifestyle Coach. An ethnically ambiguous illustrated girl greets me, gleefully eating a bowl of vegetables while holding her cell phone. Against a salmon-colored backdrop are the words: “MY DIET COACH,” offering a health plan “tailored” to my genetics.

Here is what the DNA Lifestyle Coach, run by a company called Titanovo, promises: For between $215 and $320, it will send you a saliva kit and analyze your genes to determine how you should best live your life for optimal mental and physical health, as well as optimal dental and skin care. For another $150 it will measure the length of your telomeres (the protective caps on the ends of our chromosomes, which typically shrink as we get older and are being studied to understand aging), to help you assess your longevity. You can also bypass Titanovo’s DNA test and instead merge data you’ve already received from 23andMe (as I did) or another testing company.

DNA Lifestyle Coach is one in a batch of companies that has emerged in recent years, promising to pare down confusing personal DNA data reports, using science, leaving you instead with a simple set of bullet points for how to live healthier, happier, stronger, smarter, longer.

There’s DNAFit. And Kinetic Diagnostics. And even a “genetic superhero test” by Orig3n, which makes DNA-based predictions about your strength, intelligence, and speed. Most of these are aimed at boosting athletic and physical performance and preventing sports-related injuries. But DNA Lifestyle Coach ventures into cosmetic and stress-reduction advice, seeking to answer questions like: What can our genes tell us about how we can sleep better? What secrets does my DNA hold about preventing aging?

As I begin to read my report, DNA Lifestyle Coach informs me: “Your genetics infer that you will struggle to lose weight more than most, so your caloric cut should be strict.” When dieting, it says, I should aim to take in 600 fewer calories a day.

At first glance, this information does not feel more enlightening than any other diet or fitness plan I have ever tried in my life. Plug my weight, height, BMI numbers and heart rate averages into apps like MyFitnessPal or Fitbit and each one will spit out similar estimates. Tell me something I don’t know. Then, it does.

According to my genes, it says up to three cups of coffee per day could be beneficial, but does not give any details as to those benefits. And the psychological effects of caffeine are supposedly less pronounced for me, which means I’m able to sleep after a couple hours even when having coffee at night. It also predicts that I sober up after alcohol quicker than most. Great! More coffee? Less intoxication? All from my genes?

It gets better. Apparently, I have awesome endurance. Like marathon runner-level endurance (if I wanted to be a professional athlete). And my DNA Lifestyle Coach says I push myself in exercise and competition. That is because I don’t have any risk for “over-anxiety,” or other “negative emotions.” I don’t think my husband would agree. But whatever. I am starting to like my genes even more.

Feeling emboldened, I sign up for the company’s telomere test, which requires sending more of my spit away in the mail. It will take several weeks to get the results back, but I have a feeling the test is going to tell me I have robust telomeres too, and that I am going to live a long, long time. It is all beginning to feel a lot like that time I had my palms read on a street corner in the French Quarter in New Orleans.

But those feel-good endorphins that come along with being told you’re superior can fade fast, and one need only dig down into the data to figure out that such an inflated sense of personal biology may not be much more than an illusion.

“You have to know, this is like the stuff you see on TV after midnight,” Stuart K. Kim tells me after I share my DNA Lifestyle Coach site password and complete health profile results with him. He’s a professor emeritus in the developmental biology and genetics program at Stanford University. “Weight loss kind of stuff, anti-aging kind of stuff. It’s pretty far out there.”

I stay on the phone with Kim as he and I click on the little information bubbles in my report next to suggestions for carbs, fats, fiber, water intake, vitamins, gluten, and lactose. In each category, the report highlights my genes and SNPs in those gene sequences (single-nucleotide polymorphisms, pronounced “snips,” which are alternative spellings of genes that come down to a one letter difference. That one letter may lead to the gene functioning differently). With each SNP comes a link to an abstract for a published academic paper (most behind a paywall) explaining how it might be associated with health.

Kim goes a step further for me. Using his own academic accounts, he kindly pulls up and reviews the studies. He gives the company credit for posting the links to the papers in the first place—allowing customers to check out some of the conclusions if they choose. “It is buyer beware. You can’t just take everything at face value.”

Problem is, as Kim begins to interpret the papers on my DNA Lifestyle Coach report in connection to my own SNPs, he can’t even make sense of it all. Kim has served as an editor of PLOS Genetics, as well as on the National Science Advisory Council. He even developed his own DNA interpretation site for a Stanford class he taught on genetics, which students (or the public) can use for free.

On the DNA Lifestyle Coach site, my SNPs + the studies = conclusions like: Your eating behavior is 50 percent likely to be hedonic (the kind of eating for pleasure that leads to obesity and is similar to addiction). Then it goes on to recommend the LEARN Diet for my genotype. Yet there is no clear answer on how exactly the company came to that assessment.

At one point, I hear Kim say in frustration, “Maybe they are just assuming nobody is going to actually look at what they are saying? You almost have to be a detective to sit down and figure this stuff out.”

* * *

“We try to be open and honest about where the science is,” says Corey McCarren, the chief operating officer for Titanovo. The company launched after a successful Kickstarter campaign last year. McCarren’s specialty is marketing, not genetics, but he notes that his founding partner and CEO, Oleksandr Savsunenko, has a Ph.D. in macromolecular chemistry from France’s Toulouse University, and created the company’s telomere length testing kit.

“The science is now in a place where there are very strong correlations” between particular gene variations and health outcomes, McCarren says. Big data—the analysis of large amounts of data to identify patterns and make predictions—is now being used in a multitude of industries, as McCarren points out. The company believes that big data can also be successfully “applied to genetics, using probabilistic approaches.”

Studies referenced on DNA Lifestyle Coach have been published in academic journals. But some research is better proven than others, he says, and the company tries to give weight to the stronger studies. The journals vary in distinction, the studies vary in size and scope, and some experiments have been replicated, while others–like this one on how cloudy apple juice may be healthier for some genotypes—have not.

The DNA Lifestyle Coach algorithm ranks studies, giving more weight to those that are more prominent or corroborated. As research results are updated, retracted, or reaffirmed, the algorithm will also revise and update the customer’s report. The company plans to release its mental wellness, dental, and skincare tests in a few months (so far you can just get results for diet fitness and telomeres).

In the future, it plans to incorporate personal data on every individual’s daily health behavior, if users opt in to answer questions about themselves, “much like Facebook and Google are taking all the big data from what people are doing online and making assumptions about people,” McCarren says. “That’s what we want to do. We want to discover those important correlations that will lead to people able to live their best lives.”

“We don’t show all the studies” that are referenced and averaged, Savsunenko explains, when I ask about the methodology. “The number of exact studies that we used and combined in order to generate the result — it is our proprietary thing. Although in reality most of the recommendations are based on the quite simple genetic and mathematical approaches.”

Fair enough. But the equations behind the inferences still feel a bit like voodoo.

Take my alcohol results: I will sober up quickly, and “alcohol consumption will likely lead to hangovers.” This is followed by 10 of my SNPs and links to six scholarly articles covering how genes are related to everything from drinking behavior and intensity, urges to drink, and alcoholism risk.

But DNA Lifestyle Coach fails to mention anything about the ALDH2 gene variant, which I already know I have, thanks to 23andMe. It causes a reaction known as “Asian flush.” My body lacks the enzyme that normally breaks down acetaldehyde, a toxic substance in alcohol.  It builds up to abnormal levels even after half a glass of wine, causing the blood vessels in my face begin to expand. My skin turns the color of my merlot. My heart races. Within 15 minutes, my face and chest look hot to the touch, as if I accidentally fell asleep on the beach. People with this gene variant also have an increased risk for esophageal cancer.

Kim, who also experiences the same genetic pinkish glow when he drinks alcohol, was surprised my DNA Lifestyle Coach omitted it entirely.

When I ask Savsunenko about it, he replies that most people who have this gene already know they have it. “We are trying to get into smaller details of things. But, yeah, you are right—we should include it maybe.”

No matter what you include or omit, or how you add up and average it, genomic data interpretation is an ethically thorny and legally risky business. I wanted to know, not only if these algorithmic conclusions are safe, but if they are legal.

* * *

In the most romantic of gestures, my husband bought me a 23andMe saliva kit for my birthday in 2015. That was two years after 23andMe received an FDA warning to stop interpreting specific health data from its genetic tests.

Using a medical device like a DNA kit and relying on companies’, rather than doctors’, interpretations of our unsupervised genetic information from those kits, the FDA said, might lead a patient to undergo unnecessary surgeries to prevent cancer, increase or decrease doses or stop a doctor’s prescriptions and therapy altogether.

By the time I received my 23andMe results, the company had switched to focusing more on ancestry (it told me I am 50 percent East Asian and 50 percent European—no shocker), other traits like eye color (I’m likely to have dark-colored eyes—also duh), whether I can detect taste bitter or sweet tastes (it told me I like both), or if I’m more likely to sneeze in the sun (apparently I am). My report was mildly entertaining for a few hours, but it revealed no real life-altering information. I didn’t open it again until last month, when I dumped its contents into DNA Lifestyle Coach.

By then, the FDA had softened its stance on 23andMe’s tests and granted the company approval to tell its customers whether they have an increased risk for 10 specific conditions. These include Parkinson’s, late onset Alzheimer’s, Celiac disease, and a handful of other disorders that can affect movement, blood clotting, digestion or other health issues. My updated 23andMe report offered the reassuring words “variant not detected” alongside each of the conditions.

But in the years since the legal drama first began to unfold with 23andMe, other sites were ramping up, carefully tiptoeing around the kind of rules that could get them a cease and desist letter from the FDA.

DNA Lifestyle Coach has avoided this controversy, for now, by steering clear of medical discussions, McCarren tells me. When a genetic test company tells a customer: “You have nine times more likelihood of developing heart disease—take two aspirin a day,” he believes that is when the legal terrain gets murky. DNA Lifestyle Coach “is not a product to help you manage disease,” he says. “This is a product to help you make better lifestyle decisions.”

It’s not so different from seeking advice from a personal trainer at your gym, or a diet and fitness book on Amazon, McCarren says. Maybe you will see health improvements, maybe not, but you won’t get a medical diagnosis and you won’t risk doing any real harm. The difference, he adds, is “that there is strong enough evidence there to give people useful advice, which is better than just throwing a dart at a (diet) board and saying, ‘I’ll go with this one.’”

Most of these companies rely on similar data sets and “package it in different ways to try to make it understandable,” Barry Starr, another geneticist from Stanford University, tells me. “I was trying to think of a result that would make me change my lifestyle—I couldn’t think of one.”

There is just still so much geneticists still do not know, Starr says. Just because 23andMe cleared me of variants for 10 conditions does not at all mean I won’t still develop any one of them. One gene sequence is most likely part of an orchestra of a dozen or even a hundred others (many not yet identified)—all interacting to create a particular result. We also have gene sequences that protect us—which can counteract the “bad” SNP affects.

Your environment, the way you were reared and raised, and every choice you’ve made about your life until now may have had an impact on whether some of your genes are turned on, or “expressed” (as studied in the growing field of epigenetics). And Starr tells me that different DNA sequencing companies test different genes, which could lead to contradictory predictive health outlooks.

*  *  *

In the wake of the FDA’s 23andMe ban, Kim’s students became enamored by the debate over how much you have a right to know about your own genes. Some argued “I have a right to know. It’s my DNA. I’m allowed to use my brain to look at my own DNA,” Kim tells me. But others asserted that, “interpretation can go awry. Someone could make a stupid decision and hurt themselves.”

DNA Lifestyle Coach piques my interest enough to seek out more data. For just $5, I also sign up for Promethease, a genomic information clearinghouse. Again, I plug in my 23andMe raw results.

Promethease avoids the FDA regulations imposed upon 23andMe because it does not offer the spit kit. Promethease takes the raw results from 23andMe or Ancestry.com and runs it all against published academic genetic studies in SNPedia (created by the founders of Promethease), which is like a Wikipedia for genomic data, giving you a far more sweeping view of your DNA than either 23andMe or DNA Lifestyle Coach.

When I download my Promethease file, compiled on the screen before me into a mind-numbing document of multi-colored pie graphs, are 20,269 of my SNPs, looking for associations with everything from enhanced hippocampal volume, to better performing muscles, to worse hang overs, lack of empathy, longevity and gout. They are divided by colors: red for “bad” impact, green for “good,” and grey for “not set,” or not enough information to know.

In filtering first for only the “bad” as any morbidly curious person would (is there a SNP for that?) it seems my DNA is beset by perilous risks: melanoma, ovarian cancer, depression, obesity, schizophrenia, coronary artery disease, breast cancer, lung cancer, colorectal cancer, and of course Alzheimer’s and Parkinson’s. Depending on how you look at my Promethease report, I’m also at risk for age-related macular degeneration, or I’m not. I’m at risk for developing Crohn’s Disease, or wait, maybe not. Different SNPs contradict each other.

Should I run this by a doctor? I wonder. Or a genetic counselor? What does one do with such a vomit pile of personal data?

It is this very conundrum that could give a company like DNA Lifestyle Coach—as its algorithms get more sophisticated—an upper hand with the public in the future. “We are focused on actionable results, McCarren says. “We assume our customers are not interested in just the genetic reports…we are not trying to overload you with the information.”

* * *

With my own DNA bible now at my fingertips, I still do not feel any more informed about my own health future than I did before. Despite DNA Lifestyle Coach’s fortune cookie-like predictions, I still embrace our inability to foretell most outcomes. My father has diabetes. My grandfather had heart disease. My grandmother had breast cancer. I always knew I could end up with each of these conditions, or I could dodge them altogether.

As dazzling as it is to see our DNA sequenced for so little cost, it is premature for us to map out life plans exclusively based on our genes. Of course, with science progressing so rapidly, that could change in years to come. My telomere test results, which took about two months to come back, indicate that I just might just live long enough to witness that future.

Longer telomeres have been associated with more resilient cellular health. My telomeres are longer than 59 percent of women of my age, according to the test results, which puts me in the “Very Good Zone.” It did not offer me any suggestions to improve my telomere length, although studies have found that meditation and reduced stress could have an impact. Instead, it gave me a calculation of my biological age (35), which is three years younger than my actual age. At the end of the results page, it also offered this caveat: “Keep in mind the full dynamics of telomere length have yet to be discovered.”

Article source here:The Atlantic

[healthy-insights]

Global Genomics Personalized Health Market Research Report 2024

Transparency Market Research presents this most up-to-date research on "Genomics Personalized Health Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2016 - 2024"

Genomics Personalized Health Market: Overview

Personalized genomics is a branch of genomics that is concerned with the analysis and sequencing of an individual’s genome. The genotype of an individual can be identified using various techniques such as next-generation sequencing (NGS), partial genome sequencing, single-nucleotide polymorphism (SNP) analysis, and full genome sequencing. After identifying an individual’s genotype, it is compared with published literature to determine trait expressions and the probability of acquiring certain diseases.

Personalized genomics play an imperative role in personalized and predictive medicine. With recent developments in gene sequencing techniques and data analytics, genetic testing technology is evolving rapidly. It is also expected that with the decreasing costs of genetic testing, personalized genomics is likely to become affordable for everyone in the near future, which will transform the genomics personalized health market into a highly lucrative business prospect.

Genomics Personalized Health Market: Key Segments

Some of the types of instruments generally used in personalized genomics are NGS platforms, RT-PCR, microarray, and sequencing and genetic analyzers. Some of the types of genetic tests used in personalized genomics are oncology testing, infectious disease testing, orphan disease testing, autoimmune disease testing, and obstetrics testing. Genomics personalized health market players offer various services such as genomic sequencing services, microarray services, and the software used to store the data gained from the genetic analysis.

Download Exclusive Brochure of This Report : https://goo.gl/Bk8qM7

Genomics Personalized Health Market: Region-wise Outlook

In terms of geography, North America, followed by Europe, accounts for the largest share in the global genomics personalized health market owing to the high adoption rate of genetic testing services and the high prevalence of cancer and other autoimmune diseases in developed countries. According to the American Cancer Society, in 2014, approximately 232,670 women were diagnosed with invasive breast cancer in the U.S. Additionally, the WHO reported that, in 2012, about 8.2 million people died of cancer and approximately 1.7 million women were diagnosed with breast cancer globally.

The demand for novel diagnostic and treatment solutions such as genetic testing solutions and personalized medicine is expected to remain high in developed countries such as the U.S, Germany and the U.K. in the coming years. However, other regions such as Asia Pacific, the Middle East, and Latin America are expected to become major markets in the near future, owing to the increasing demand for advanced diagnostics solutions and research applications.

Genomics Personalized Health Market: Drivers and Restraints

The genomics personalized health market has witnessed significant growth in the last few years. The major factor propelling the genomics personalized health market is the expanding application of genomic testing and research.

Moreover, other factors such as technological advancements in whole genome and next-generation sequencing and the growing consumer adoption rate are also contributing to the growth of the genomics personalized health market. Furthermore, favorable reimbursement models, increasing government investments in genetic research projects and the implementation of better regulatory policies in approval pathways are driving the genomics personalized health market. However, factors such as the high cost of gene sequencing, delay in regulatory approvals, and the decreasing average selling prices of genomics services and instruments are some of the factors that can hinder the growth of the genomics personalized health market.

Genomics Personalized Health Market: Competitive Insight

Presently, the global genomics personalized health market is highly competitive owing to the involvement of many established players. The major companies involved in the genomics personalized health market are Bio-Rad Laboratories, Inc., Eastern Biotech & Life Sciences, Gene By Gene, LTD., Genelex Corporati on, Genetic Technologies Group, Genotek, InoLife Technologies, Inc., Illumina, Inc., Indian Biosciences, Invitae, Interleukin Genetics, Life Technologies, Corp., Knome, Inc., Roche Diagnostic, QIAGEN, uBiome, Inc., Xcode Life Sciences.

Browse Global Strategic Business Report: https://goo.gl/T9O0AQ

About Us

Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants, use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

Each TMR syndicated research report covers a different sector - such as pharmaceuticals, chemicals, energy, food & beverages, semiconductors, med-devices, consumer goods and technology. These reports provide in-depth analysis and deep segmentation to possible micro levels. With wider scope and stratified research methodology, TMR’s syndicated reports strive to provide clients to serve their overall research requirement.

US Office Contact

90 State Street, Suite 700

Albany, NY 12207

Tel: +1-518-618-1030

USA - Canada Toll Free: 866-552-3453

Email: sales@transparencymarketresearch.com

Website: www.transparencymarketresearch.com

[healthy-insights]

Genomics Personalized Health Market - Emerging Market Trends, Size, Share and Growth Analysis

Genomics Personalized Health Market: Overview

Personalized genomics is a branch of genomics that is concerned with the analysis and sequencing of an individual’s genome. The genotype of an individual can be identified using various techniques such as next-generation sequencing (NGS), partial genome sequencing, single-nucleotide polymorphism (SNP) analysis, and full genome sequencing. After identifying an individual’s genotype, it is compared with published literature to determine trait expressions and the probability of acquiring certain diseases.

Genomics Personalized Health Market: Drivers and Restraints

The genomics personalized health market has witnessed significant growth in the last few years. The major factor propelling the genomics personalized health market is the expanding application of genomic testing and research.

Moreover, other factors such as technological advancements in whole genome and next-generation sequencing and the growing consumer adoption rate are also contributing to the growth of the genomics personalized health market. Furthermore, favorable reimbursement models, increasing government investments in genetic research projects and the implementation of better regulatory policies in approval pathways are driving the genomics personalized health market. However, factors such as the high cost of gene sequencing, delay in regulatory approvals, and the decreasing average selling prices of genomics services and instruments are some of the factors that can hinder the growth of the genomics personalized health market.

Browse the full Genomics Personalized Health Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2016 - 2024 report at http://www.transparencymarketresearch.com/personalized-genomics-market.html

Genomics Personalized Health Market: Key Segments

Some of the types of instruments generally used in personalized genomics are NGS platforms, RT-PCR, microarray, and sequencing and genetic analyzers. Some of the types of genetic tests used in personalized genomics are oncology testing, infectious disease testing, orphan disease testing, autoimmune disease testing, and obstetrics testing. Genomics personalized health market players offer various services such as genomic sequencing services, microarray services, and the software used to store the data gained from the genetic analysis.

Genomics Personalized Health Market: Competitive Insight

Presently, the global genomics personalized health market is highly competitive owing to the involvement of many established players. The major companies involved in the genomics personalized health market are Bio-Rad Laboratories, Inc., Eastern Biotech & Life Sciences, Gene By Gene, LTD., Genelex Corporation, Genetic Technologies Group, Genotek, InoLife Technologies, Inc., Illumina, Inc., Indian Biosciences, Invitae, Interleukin Genetics, Life Technologies, Corp., Knome, Inc., Roche Diagnostic, QIAGEN, uBiome, Inc., Xcode Life Sciences.

About Us

Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants, use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

Each TMR syndicated research report covers a different sector - such as pharmaceuticals, chemicals, energy, food & beverages, semiconductors, med-devices, consumer goods and technology. These reports provide in-depth analysis and deep segmentation to possible micro levels. With wider scope and stratified research methodology, TMR’s syndicated reports strive to provide clients to serve their overall research requirement.

US Office Contact

90 State Street, Suite 700

Albany, NY 12207

Tel: +1-518-618-1030

USA - Canada Toll Free: 866-552-3453

Email: sales@transparencymarketresearch.com

Website: http://www.transparencymarketresearch.com/

[healthy-insights]

Genomics Personalized Health Market - Emerging Market Trends, Size, Share and Growth Analysis

Genomics Personalized Health Market: Overview

Personalized genomics is a branch of genomics that is concerned with the analysis and sequencing of an individual’s genome. The genotype of an individual can be identified using various techniques such as next-generation sequencing (NGS), partial genome sequencing, single-nucleotide polymorphism (SNP) analysis, and full genome sequencing. After identifying an individual’s genotype, it is compared with published literature to determine trait expressions and the probability of acquiring certain diseases.

Genomics Personalized Health Market: Drivers and Restraints

The genomics personalized health market has witnessed significant growth in the last few years. The major factor propelling the genomics personalized health market is the expanding application of genomic testing and research.

Moreover, other factors such as technological advancements in whole genome and next-generation sequencing and the growing consumer adoption rate are also contributing to the growth of the genomics personalized health market. Furthermore, favorable reimbursement models, increasing government investments in genetic research projects and the implementation of better regulatory policies in approval pathways are driving the genomics personalized health market. However, factors such as the high cost of gene sequencing, delay in regulatory approvals, and the decreasing average selling prices of genomics services and instruments are some of the factors that can hinder the growth of the genomics personalized health market.

Browse the full Genomics Personalized Health Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2016 - 2024 report at http://www.transparencymarketresearch.com/personalized-genomics-market.html

Genomics Personalized Health Market: Key Segments

Some of the types of instruments generally used in personalized genomics are NGS platforms, RT-PCR, microarray, and sequencing and genetic analyzers. Some of the types of genetic tests used in personalized genomics are oncology testing, infectious disease testing, orphan disease testing, autoimmune disease testing, and obstetrics testing. Genomics personalized health market players offer various services such as genomic sequencing services, microarray services, and the software used to store the data gained from the genetic analysis.

Genomics Personalized Health Market: Competitive Insight

Presently, the global genomics personalized health market is highly competitive owing to the involvement of many established players. The major companies involved in the genomics personalized health market are Bio-Rad Laboratories, Inc., Eastern Biotech & Life Sciences, Gene By Gene, LTD., Genelex Corporation, Genetic Technologies Group, Genotek, InoLife Technologies, Inc., Illumina, Inc., Indian Biosciences, Invitae, Interleukin Genetics, Life Technologies, Corp., Knome, Inc., Roche Diagnostic, QIAGEN, uBiome, Inc., Xcode Life Sciences.

About Us

Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants, use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

Each TMR syndicated research report covers a different sector - such as pharmaceuticals, chemicals, energy, food & beverages, semiconductors, med-devices, consumer goods and technology. These reports provide in-depth analysis and deep segmentation to possible micro levels. With wider scope and stratified research methodology, TMR’s syndicated reports strive to provide clients to serve their overall research requirement.

US Office Contact

90 State Street, Suite 700

Albany, NY 12207

Tel: +1-518-618-1030

USA - Canada Toll Free: 866-552-3453

Email: sales@transparencymarketresearch.com

Website: http://www.transparencymarketresearch.com/